Mometasone furoate with indacaterol and glycopyrronium
Brand: Enerzair Breezhaler
PBAC's latest decision on Mometasone furoate with indacaterol and glycopyrronium: Recommended with restriction (2020). Considered for Maintenance therapy of severe asthma in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2020
Submissions
1
2020 → 2020
Eligible population
Adults aged 18 years and over with severe asthma who have experienced at least one severe exacerbation requiring documented use of systemic corticosteroids in the previous 12 months while receiving optimised asthma therapy (at least 800 micrograms budesonide per day or equivalent with a long-acting beta2-agonist) despite formal assessment of and adherence to correct inhaler technique.
Therapy area
Respiratory
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
FEV1
Key trials
Iridium, Argon
Comparator
fluticasone propionate 500/50 micrograms with salmeterol one actuation twice daily plus tiotropium 2.5 micrograms two inhalations once daily
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.